Skip to main content
ACAD
NASDAQ Life Sciences

Acadia's Rett Syndrome Drug Daybue Wins Positive EU Opinion After Reexamination

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$27.32
Mkt Cap
$4.062B
52W Low
$19.69
52W High
$28.35
52W Position info
39% above low
Off High info
3.6% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

ACAD sits 39% above its 52-week low of $19.69.

Summary

Acadia Pharmaceuticals' Rett syndrome drug, Daybue (trofinetide), received a positive opinion from the European Medicines Agency's CHMP after a reexamination, recommending marketing authorization in the EU. This is a significant reversal from the negative EU regulatory opinion for Daybue that was confirmed in the company's Q1 2026 10-Q filing on May 7th. The news is driving a 13% premarket surge in shares. This development materially expands the drug's potential market and revenue stream. The European Commission is expected to issue a final decision in the coming months.

At the time of this announcement, ACAD was trading at $27.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1B. The 52-week trading range was $19.69 to $28.35. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

ACAD - Latest Insights

ACAD
Nov 16, 2026, 1:38 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $18.79
Real-time Price: $17.12 info
Change: -$1.67 (-9%) info
Market Cap: $2.957B info
ACAD
Nov 04, 2026, 6:16 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $21.95
Real-time Price: $17.12 info
Change: -$4.83 (-22%) info
Market Cap: $2.957B info
ACAD
Nov 04, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $21.46
Real-time Price: $17.12 info
Change: -$4.34 (-20%) info
Market Cap: $2.957B info
ACAD
Oct 05, 2026, 2:23 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $20.07
Real-time Price: $17.12 info
Change: -$2.95 (-15%) info
Market Cap: $2.957B info
ACAD
Sep 28, 2026, 4:05 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $20.53
Real-time Price: $17.12 info
Change: -$3.41 (-17%) info
Market Cap: $2.957B info